Warning climate change could keep bull sharks in Sydney waters ‘year-round'
The James Cook University research shows that bull sharks, which spend their winters in Queensland, are now on average staying 15 days longer off Sydney's coast in the summer than they did 15 years ago.
JCU postdoctoral research fellow Nicolas Lubitz said rising water temperatures were to blame.
'We did a climate analysis of water temperatures of the coast around Sydney and found that average temperatures during the period from October-May each year have been increasing over the past 40 years,' he said.
'We've been tracking migratory bull sharks moving seasonally between Queensland and NSW, specifically the area off Sydney for 15 years, and now on average they're staying 15 days longer than they used to back in 2009.'
The change in migration patterns would extend the potential for human-shark encounters, Dr Lubitz warned.
'Sydney is Australia's most populated city, where bull sharks disappear during the wintertime and migrate back to Queensland during the cooler months, as bull sharks avoid long-term temperatures below 19 degrees,' he said.
'But if they're staying longer, it means that people and prey animals have a longer window of overlap with them.'
According to the Australian Shark Incident Database, nearly all shark encounters in Sydney Harbour with humans involve bull sharks.
They are considered one of the world's most dangerous and aggressive shark species.
In March this year, Sydney woman Mangyon Zhang was attacked by a bull shark at Gunyah Beach, Bundeena, south of Sydney.
Ms Zhang survived the attack.
'She has quite a severe laceration to her outer right leg, to the bone, calf and thigh, and inside thigh,' her partner Maria Masutti said in a social media post.
'She lost quite a lot of blood and had transfusions.'
Dr Lubitz also said if warming trends persisted, bull sharks could inhabit the waters off Sydney 'year-round'.
'While the chances of a shark bite, and shark bites in Australia in general, remain low, it just means that people have to be more aware of an increased window of bull shark presence in coastal waters off Sydney,' he said.
Wildlife scientist Vanessa Pirotta said the research could inform how the public interacted with the marine environment.
'As a whale scientist as well, a lot of these animals are economically profitable for us,' Dr Pirotta told NewsWire.
'People will pay to swim with sharks, people will pay to whale watch.
'Their presence is so important for us, not only ecologically but also economically.'
Dr Lubitz also said the changing climate could alter bull shark breeding patterns, pushing the predators to new breeding grounds further south.
'If that trend persists, there's a fair chance that a lot more tropical species are going to be pretty much year-round in the Sydney area, which obviously changes the whole dynamic,' he added.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

ABC News
an hour ago
- ABC News
Hobart has the highest incidence of multiple sclerosis in Australia, could our DNA provide the answers?
Tennille Luke Hobart has one of the highest rates of MS in Australia. And while genetics can play a role, the evidence points more strongly to environmental factors. So one of the key reasons is Hobart's latitude, it's quite southern, and so there's less sunlight, which means there's lower vitamin D levels, and that's a known risk factor for developing MS. So this geographic pattern has also been seen globally, not just in Australia. So that's why research like this is important, especially in Tasmania, where MS is more common. If we can detect biological changes before symptoms appear, we might be able to intervene earlier and improve outcomes. It's about understanding who is at risk of developing MS based on their DNA, and how the immune system responds to common viruses. So what it does highlight is the importance of early detection and personalised research. And the more we understand genetic risks, the better we'll be able to support people with MS in the future. Kylie Baxter And just one thing more coming back to the UV exposure. So vitamin D, how is it that lack of vitamin D can increase the risk of developing MS? What is the link there? Why is that? Tennille Luke That is a really good question. And we're all trying to understand that in more detail. There is a link in the immune system, but scientists are still trying to answer that. And I'm not exactly the expert to answer that. So it's an ongoing research area. And we're still trying to understand the link there.

Sydney Morning Herald
an hour ago
- Sydney Morning Herald
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.

The Age
an hour ago
- The Age
NeuroScientific locks in deal to scale-up stem cell production
Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals has started transferring its patented StemSmart process to one of Australia's biggest and most experienced cell therapy manufacturers to scale up clinical-grade production. Queensland-based Q-Gen Cell Therapeutics will take over the manufacturing of StemSmart's specific mesenchymal stromal stem cells (MSC) from Royal Perth Hospital's Cell and Tissue Centre. NeuroScientific says the technology transfer will allow it to establish MSC manufacturing for its StemSmart infusions for further clinical trials and pursue commercial opportunities. The MSC technology was developed as a last-line infusion treatment for critically ill patients, including those experiencing severe immune complications from bone marrow transplants, kidney and lung transplant rejection and inflammatory Crohn's disease. 'This relationship will allow the company to scale the manufacturing of its StemSmart technology.' NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith NeuroScientific acquired the StemSmart technology in late June via its $4.1 million acquisition of unlisted Perth-based stem cell company Isopogen. Isopogen had previously signed a manufacturing contract with QIMR Berghofer, under which Q-Gen undertook manufacturing process development to scale up clinical-grade production of the StemSmart platform. Q-Gen, located in QIMR in Brisbane, has more than 25 years of experience in cell therapy manufacturing for industry. The laboratory specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control. NeuroScientific Biopharmaceuticals chief executive officer Nathan Smith said: 'We are very pleased to be partnering with Q-Gen given their extensive experience in manufacturing, process development and GMP production of biologic products for clinical trials. This relationship will allow the company to scale the manufacturing of its StemSmart technology to address substantial market opportunities.' StemSmart offers a step up from traditional MSC manufacturing in that the cells are grown in a special medium, becoming activated in the process. The platform technology was developed at Royal Perth Hospital and manufactured using the hospital's processes.